Cytokinetics Inc. (CYTK) Stock Analysis
Market Closed
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy28 analystsWhat's happening with CYTK
Price History
5-Year Weekly Candlestick Chart
Profile
profitability, earnings quality, valuation and growth lag behind.
How is each axis scored?
- Valuation20/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-5.8%)0/25
- P/S (89.2x)0/25
- EV/EBIT (n/a)10/25
- Growth20/100 · Weak
- Revenue CAGR (12.1%)20/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (n/a)0/25
- ROE (n/a)0/25
- Net margin (-784.0%)0/25
- Operating margin (-605.1%)0/25
- Financial Health53/100 · Moderate
- Altman Z (-3.92)3/25
- Current ratio (4.21)25/25
- Interest coverage (-14.3x)0/25
- Net cash / debt (Net cash)25/25
- Quality11/100 · Weak
- Piotroski F (2/9)5/25
- Beneish M (-0.83)6/25
- FCF conversion (n/a)0/25
- Margin stability (σ 5566.4%)0/25
About Cytokinetics Inc.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Show more
The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Headquarters: SOUTH SAN FRANCISCO, CA · Employees: 673 · Website ↗
Insider Transactions
Recent SEC Form 4 filings
- SellOption exercise · filed 2026-08-31-10000 sh2026-08-31
- SellOpen market sale · filed 2026-08-31-10000 sh2026-08-31
- BuyOption exercise · filed 2026-08-31+10.0K sh2026-08-31
- SellOption exercise · filed 2026-08-31-7500 sh2026-08-31
- SellOpen market sale · filed 2026-08-31-7500 sh2026-08-31
+3 more recent filings
Key Metrics
Financial snapshot — pillar inputs plus per-share and market context
Valuation
20EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF164.8xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-5.8%D
Grade D: NegativeTTM FCF / Market Cap — vs own 5Y history: -17228.0%–-4285.5% · highest in history
P/S (TTM)89.21xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 0.0x–1.3x · highest in history
EV/EBITDA1233.4xD
Grade D: ExpensiveEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales152.9xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B RatioNeg. EquityC
Grade C: BuybacksPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-0.23A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROENeg. EquityC
Grade C: BuybacksReturn on Equity. Neg. equity = heavy buybacks
ROA-59.0%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-784.0%D
Grade D: LowNet Income / Revenue
Operating Margin-605.1%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin—
Gross Profit / Revenue
FCF Margin-200.0%D
Grade D: LowFCF / Revenue
True FCF Margin-631.4%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Financial Health
53CAltman Z-Score-3.92D
Grade D: DistressBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio4.21xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio4.45xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-14.3xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT0.9xA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity—
Debt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt3.31xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Growth
20ERevenue CAGR12.1%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Implied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue112.6%D
Grade D: HighTTM stock-based comp / TTM Revenue
Quality
8/9 Loss Years11EPiotroski F-Score2/9D
Grade D: WeakFinancial strength 0–9. >7 Strong
Beneish M-Score-0.83D
Grade D: RiskyEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability5566.4%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue23.7%D
Grade D: HeavyTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.06xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
More metrics — Per Share, Balance Sheet, MarketHide additional metrics
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$7.18
Cash & short-term investments per share (Finnhub)
Book Value / Share$2.88
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$247.21M
Total debt obligations (short + long term)
Cash & Equiv.$818.55M
Cash and short-term investments
Net Debt$-571.34MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$-826.57M
Shareholders' equity (book value)
Asset / Liability0.61xD
Grade D: RiskyTotal Assets / Total Liabilities
Market
Market Cap$9.44B
Current Market Capitalization
Beta0.39B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
Takeaway
Neutral
Company is effectively debt-free after netting cash.
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Mar 2026 · Ratio snapshot Sep 23, 2026
Key Insights: Cytokinetics Inc. (CYTK)
Composite verdict for Cytokinetics Inc.: Neutral. Cytokinetics Inc. meets only 2 of 9 Piotroski F-Score criteria — a sign of weak underlying fundamentals. Altman Z-Score of -3.92 is below the 1.81 distress threshold — an elevated financial-risk flag. Beneish M-Score of -0.83 is above the −1.78 flag threshold, a signal that reported earnings warrant closer scrutiny. Free-cash-flow margin is negative (-200%) — the business currently burns cash.
- Company is effectively debt-free after netting cash.
- Interest coverage of -14.3× leaves little room for earnings shocks.
- Cytokinetics Inc. posted a net loss in 8 of 9 available completed fiscal years (2016–2025).
- At a valuation score of 20/100, CYTK trades at a premium to its historical multiples.
See how CYTK ranks on the Capex Tracker — top 50 capital spenders compared.
No significant market moves for CYTK in the last 30 days.
See CYTK move history →Frequently Asked Questions about CYTK
Is CYTK stock a buy right now?
PreMarketPrice's quantitative model rates Cytokinetics Inc.'s financial health at 53/100 — Neutral. This is a data-driven snapshot of fundamentals, not investment advice.
Is CYTK stock overvalued?
Cytokinetics Inc. trades at a trailing P/E of n/a and our valuation score rates it 20/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Cytokinetics Inc. report earnings?
No confirmed earnings date is currently scheduled for CYTK. The Earnings section lists recent reports and updates as dates are announced.
What sector does Cytokinetics Inc. operate in?
Cytokinetics Inc. operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Cytokinetics Inc. do?
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
About Cytokinetics Inc. (CYTK) Stock
Cytokinetics Inc. (CYTK) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. Real-time pricing data for Cytokinetics Inc. is available on this page with a market capitalization of $9.4 billion. The financial health score for CYTK is 53/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for CYTK stock.
CYTK Stock Analysis & Key Metrics
On PreMarketPrice, you can track Cytokinetics Inc. (CYTK) across multiple dimensions:
- Pre-market price & movement: Real-time CYTK stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for CYTK with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Cytokinetics Inc. across multiple reporting periods.
- Financial health score: A composite score of 53/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for CYTK.
- Sector peers: Compare CYTK against 10 other healthcare stocks on key financial metrics.
Is CYTK a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Cytokinetics Inc. (CYTK) as an investment. The financial health score of 53/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Cytokinetics Inc. (CYTK) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.